Andrea began her research career at Immune Design in 2012, where she worked in the in vivo biology department. Her work centered on investigating vector induced CD4+ and CD8+ T-cell responses, drug efficacy and dosing to support four IND submissions. In 2021 Andrea graduated with her PhD in Biomedical Sciences from Icahn School of Medicine – Mount Sinai. There she made significant contributions, exploring the impact of exosomes on immunogenicity during influenza infection, identifying neutralizing antibodies and small molecules capable of blocking entry and replication of human cytomegalovirus (HCMV), and identifying unique cross-reactive epitopes that arise during HCMV infection. In 2022, Andrea joined L-Seagen (now Pfizer), to work on potency assay development. She specializes in developing cytotoxicity assays, engineering cell lines and creating novel bioassays for secondary mechanisms of action.